SeaStar Medical Holding Corporation ICU PHARMA
Company Overview
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
Recent Developments
- Dec 2025 Revenue of $1.23M (+814.1% YoY); net profit $-12.15M.
- Trailing 12 Months Year-on-year growth — revenue +82.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 82.00% |
Stock Price Performance
| 1 Year: | -59.42% |
| 6 Months: | +11.74% |
| 3 Months: | +1.72% |
| 1 Month: | -10.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.00 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 76.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ICU SeaStar Medical Holding Corporation PHARMA | 2.95 | -1.56 | $13.00M | 0.00% | -116.89% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 68.00K | 293.00K | 338.00K | 183.00K | 495.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 68.00K | 293.00K | 311.00K | 169.00K | 449.00K |
| Operating Income | -5.24K | -125.96K | -209.72K | -411.40K | -812.00K | -1.31M | -1.77M | -4.58M | -3.75M | -2.94M | -3.95M | -4.67M | -4.46M | -3.82M | -1.76M | -3.58M | -3.60M |
| Net Income | - | 1.71M | -1.98M | 235.98K | -1.00M | -902.00K | -1.89M | -7.10M | -2.45M | -7.23M | -12.70M | -3.24M | -4.48M | -3.77M | -2.00M | -3.47M | -3.52M |
| Diluted EPS | - | 0.18 | - | - | -0.14 | -0.12 | -0.26 | -0.54 | -4.10 | -9.02 | -4.73 | -1.03 | -1.10 | -0.44 | -0.18 | - | - |
| R&D Expense | - | - | - | - | 355.00K | 596.00K | 727.00K | 1.73M | 1.98M | 1.09M | 1.70M | 2.33M | 2.34M | 2.43M | 1.04M | 1.85M | 2.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | - | 0 | 135.00K | 1.23M |
| Gross Profit | - | - | 0 | 135.00K | 1.18M |
| Operating Income | -4.45M | -11.61M | -14.21M | -17.84M | -12.18M |
| Net Income | -4.60M | -12.19M | -26.23M | -24.83M | -12.15M |
| Diluted EPS | -0.63 | -1.48 | -30.26 | -6.63 | - |
| R&D Expense | 2.77M | 2.50M | 5.97M | 9.11M | 7.52M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 269.21K | 603.00K | 3.04M | 3.65M | 2.60M | 2.51M | 3.51M | 4.66M | 14.16M |
| Total Equity | 1.77M | -2.82M | -20.76M | -23.38M | -11.76M | -16.02M | -13.87M | -2.18M | 10.42M |
| Cash & Equivalents | 38.39K | 51.57K | - | - | - | - | - | - | - |
| Long Term Debt | - | - | 7.65M | - | - | - | 4.14M | - | - |
| Total Liabilities | 249.44K | 3.42M | 23.80M | 27.02M | 14.35M | 18.52M | 17.38M | 6.84M | 3.74M |
| Current Liabilities | 249.44K | 3.12M | 16.15M | 21.28M | 14.35M | 12.80M | 13.05M | 6.84M | 3.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -5.11M | -7.79M | -10.29M | -16.01M | -13.60M |
| Investing Cash Flow | -105.57M | - | - | - | - |
| Financing Cash Flow | 2.82M | 7.33M | 10.41M | 17.65M | 23.76M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 100.0% | 95.7% |
| Operating Margin % | - | - | - | -13,216.3% | -986.6% |
| Net Margin % | - | - | - | -18,392.6% | -984.6% |
| ROE % | 163.2% | 58.7% | 189.1% | 1,137.4% | -116.6% |
| ROCE % | 176.8% | 88.6% | 149.1% | 817.3% | -116.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 1.13% | 49.59K | $175.56K |
| 2 | Vanguard Capital Management LLC | 0.75% | 33.09K | $117.14K |
| 3 | UBS Group AG | 0.71% | 31.40K | $111.15K |
| 4 | Vanguard Fiduciary Trust Co | 0.31% | 13.69K | $48.47K |
| 5 | Jane Street Group, LLC | 0.29% | 12.63K | $44.72K |
| 6 | Northern Trust Corporation | 0.24% | 10.40K | $36.82K |
| 7 | PNC Financial Services Group, Inc. | 0.11% | 4.94K | $17.50K |
| 8 | Tower Research Capital LLC (TRC) | 0.03% | 1.36K | $4.80K |
| 9 | Blackrock Inc. | 0.02% | 913 | $3.23K |
| 10 | Osaic Holdings Inc. | - | 195 | $690 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ICU
ICU Medical (NASDAQ: ICUI) officer plans $819K stock sale - Stock Titan
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOd2gtZ21HNWo5aFIwd1pJQWgwTHFnalZQVUxXelBCelpWT1Q0TU9OaTNXazFVNGFtU2pTQk1CSVA4ZmxEc2hJVVdRZ3cwYlVKRHU2b2pKYlRsUnBiZzVRUUFPUlJEQXg5OGNyNkJFVml2X3UxWDcyajNaWEFmU05BVnNsQzRBSTBVRzVSNE…
ICU Medical (ICUI) Shares Skyrocket, What You Need To Know - StockStory
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQczg4YVF4Nm05UXJ3c1ZSRGlUYWVqV0NDN3lZdUdTWnVoMlhvSDhsOEVqUnpMMTdEQWFaekU1QlZHQlkxS0FFY04yY0prWEk1Y1pJNm1MYUR6bGNyMlpTQjFHX3R0aXFiRzdSVXB2bVFIam1oSmZOblhQOWV4OUlhR2hyOG9vNkV0c29rZ0…
ICU Medical (ICUI) Stock Valuation Check After Recent Momentum And Discount To Estimated Fair Value - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQeDZjdVU3Ulh0dHViWVpRdk1OdnpFSlhkZjZwMTdSeUdBdVBYSWN0ZGFEZHFEaVk4UmsybW1uRklVZmtoZ19UMFhsLUZvZTVyWUlVbDZwNmFBT1N2UExGMkVnZ0pCNVFtMlZBZ3M5SGc2UDY4Qm9DYnpoUHdJeThScTVlUnY5Q05PdGdsXz…
Icu medical chief financial officer Brian Bonnell sells $1.1 million in stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPdUg4czBmTkNQSHAyRW1uYzRIcnFCd2xuQjctM3dIODk2dnZqTlpsRC1QalhlX1ZnNkVqTFNYVlRoNllxZ0ZPYmprUFpTdUx3azdvM2pSZzlhSDNmeHNaakI1S2ZHRXNXMklXWmVlRDNIZmFBOEp6dnFJS29CaV9sdENHOTYyZGZWaDBnS2…
SEASTAR MEDICAL HOLDING ($ICU) Releases Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNTWd0NmVRVzBxR1NGc3ByN3Q0SU5OZGstTjFuOXVsbkhHOGtrbEdidHQ1TnJCUWJNS25WNGxzc0ptM0N6UTVKT3dtYnZPakk0ZjJDWlNRblhDcGJjVlJKc29HV0U3bWNTeXVBQ1Z6dnRWRW0yaDVBSUJhbl9VM1lfSlRZeUMyNmYxdmw3R1…
ICU Medical (ICUI) legal chief sells stock under preset plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQZFdUTXhIVzJDNzNSM2JRWXoxbkNCMG5idDdQWUEweEkxWXFabG1oYU5uaExpM181V0MzMWNoalJDckRjc3dsanpVZVZkUVFNd25rZWRlYzBfUDVqTzl2bkNISHAzU1pId1l0Y0xwXzN0RkRCV0lyX0hlMG5jUlRkdklFUVUweU9pbEtkZG…
ICU — Frequently Asked Questions
What is the current share price of SeaStar Medical Holding Corporation (ICU)?
As of 2026-09-19 21:16 PDT, SeaStar Medical Holding Corporation (ICU) trades at $2.95 on NasdaqCM. Its 52-week range is $2.21 to $12.40.
What is the market capitalisation of ICU?
SeaStar Medical Holding Corporation (ICU) has a market capitalisation of $13.00M on NasdaqCM.
What is the P/E ratio of ICU?
ICU trades at a trailing price-to-earnings (P/E) ratio of -1.56. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.51.
Is ICU a good stock to buy?
This page provides a data-driven analysis of SeaStar Medical Holding Corporation (ICU), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.